IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0085245.html
   My bibliography  Save this article

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations

Author

Listed:
  • Wenhua Liang
  • Xuan Wu
  • Wenfeng Fang
  • Yuanyuan Zhao
  • Yunpeng Yang
  • Zhihuang Hu
  • Cong Xue
  • Jing Zhang
  • Jianwei Zhang
  • Yuxiang Ma
  • Ting Zhou
  • Yue Yan
  • Xue Hou
  • Tao Qin
  • Xiaoxiao Dinglin
  • Ying Tian
  • Peiyu Huang
  • Yan Huang
  • Hongyun Zhao
  • Li Zhang

Abstract

Background: Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib, gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced non-small-cell lung cancer (NSCLC) who harbor EGFR mutations. However, no head to head trials between these TKIs in mutated populations have been reported, which provides room for indirect and integrated comparisons. Methods: We searched electronic databases for eligible literatures. Pooled data on objective response rate (ORR), progression free survival (PFS), overall survival (OS) were calculated. Appropriate networks for different outcomes were established to incorporate all evidences. Multiple-treatments comparisons (MTCs) based on Bayesian network integrated the efficacy and specific toxicities of all included treatments. Results: Twelve phase III RCTs that investigated EGFR-TKIs involving 1821 participants with EGFR mutation were included. For mutant patients, the weighted pooled ORR and 1-year PFS of EGFR-TKIs were significant superior to that of standard chemotherapy (ORR: 66.6% vs. 30.9%, OR 5.46, 95%CI 3.59 to 8.30, P

Suggested Citation

  • Wenhua Liang & Xuan Wu & Wenfeng Fang & Yuanyuan Zhao & Yunpeng Yang & Zhihuang Hu & Cong Xue & Jing Zhang & Jianwei Zhang & Yuxiang Ma & Ting Zhou & Yue Yan & Xue Hou & Tao Qin & Xiaoxiao Dinglin & Y, 2014. "Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations," PLOS ONE, Public Library of Science, vol. 9(2), pages 1-11, February.
    • Handle: RePEc:plo:pone00:0085245
    DOI: 10.1371/journal.pone.0085245
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0085245
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0085245&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0085245?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Ming Li & Qian Zhang & Peifang Fu & Ping Li & Aimei Peng & Guoliang Zhang & Xiaolian Song & Min Tan & Xuan Li & Yang Liu & Yueping Wu & Suyun Fan & Changhui Wang, 2012. "Pemetrexed plus Platinum as the First-Line Treatment Option for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials," PLOS ONE, Public Library of Science, vol. 7(5), pages 1-8, May.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Marscha S. Holleman & Maiwenn J. Al & Remziye Zaim & Harry J. M. Groen & Carin A. Uyl-de Groot, 2020. "Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(1), pages 153-164, February.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      More about this item

      Statistics

      Access and download statistics

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0085245. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.